This website uses third-party profiling cookies to provide services in line with the preferences you reveal while browsing the Website. By continuing to browse this Website, you consent to the use of these cookies. If you want to object such processing, please read the instructions described in our Cookie Policy.
I ACCEPT

Paolo Paoletti

GammaDelta Therapeutics

Paoletti, 68, was coaxed out of academic medicine to join Eli Lilly’s oncology unit. He eventually became vice-president of the company before moving to pharma giant Glaxo Smith Kline. Today he is chief executive of one of London’s most exciting biotech companies — GammaDelta Therapeutics — which is on the front line of cancer research. It has already won $100m of investment from backers including Japanese pharma giant Takeda.

Request a Test Drive, a Quote or More Information